LYTIR

Insider · SEC Form 4 · 10% Owner

MPM BioVentures 2014, L.P.

In the 12 months to Nov 19, 2026, on the open market: sold $3.6M of TRDA. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $3.6M in total.Aug: Insider sales $1.1MSep: Insider sales $2.5MDecJanFebMarAprMayJunJulAugSepOctNov$2.5M
Insider purchases above the line: $0Insider sales below: $3.6M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. TRDASold: Entrada Therapeutics, Inc. Sep 9, 2026 28,837 shares filed Sep 9, 2026 3,885,115 shares held indirectly after, as filed filing $206K
  2. TRDASold: Entrada Therapeutics, Inc. Sep 8, 2026 192,500 shares filed Sep 9, 2026 3,913,952 shares held indirectly after, as filed filing $1.4M
  3. TRDASold: Entrada Therapeutics, Inc. Sep 4, 2026 38,500 shares filed Sep 9, 2026 4,106,452 shares held indirectly after, as filed filing $274K
  4. TRDASold: Entrada Therapeutics, Inc. Sep 3, 2026 32,263 shares filed Sep 3, 2026 4,144,952 shares held indirectly after, as filed filing $231K
  5. TRDASold: Entrada Therapeutics, Inc. Sep 2, 2026 25,131 shares filed Sep 3, 2026 4,177,215 shares held indirectly after, as filed filing $181K
  6. TRDASold: Entrada Therapeutics, Inc. Sep 1, 2026 29,088 shares filed Sep 3, 2026 4,202,346 shares held indirectly after, as filed filing $205K
  7. TRDASold: Entrada Therapeutics, Inc. Aug 31, 2026 44,259 shares filed Aug 31, 2026 4,231,434 shares held indirectly after, as filed filing $309K
  8. TRDASold: Entrada Therapeutics, Inc. Aug 28, 2026 3,733 shares filed Aug 31, 2026 4,275,693 shares held indirectly after, as filed filing $26K
  9. TRDASold: Entrada Therapeutics, Inc. Aug 27, 2026 38,922 shares filed Aug 31, 2026 4,279,426 shares held indirectly after, as filed filing $280K
  10. TRDASold: Entrada Therapeutics, Inc. Aug 26, 2026 14,569 shares filed Aug 26, 2026 4,318,348 shares held indirectly after, as filed filing $103K
  11. TRDASold: Entrada Therapeutics, Inc. Aug 25, 2026 26,522 shares filed Aug 26, 2026 4,332,917 shares held indirectly after, as filed filing $200K
  12. TRDASold: Entrada Therapeutics, Inc. Aug 24, 2026 21,623 shares filed Aug 26, 2026 4,359,439 shares held indirectly after, as filed filing $159K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. TRDAMPM BioVentures 2014, L.P. filed Sep 10, 2026 Schedule 13D/A may seek influence 3,885,115 shares issuer: ENTRADA THERAPEUTICS, INC. filing 9.9%